Kamada Ltd.
KMDA
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics. Kamada Ltd. develops, manufactures, and markets a portfolio of marketed products for rare and serious conditions, with treatments used in areas such as lung disease, immunology, infectious disease prophylaxis, and critical care. The company’s commercial offering includes proprietary plasma-derived therapies and a distribution segment that markets additional biopharmaceutical products in selected international markets. Kamada Ltd. also operates manufacturing capabilities centered on plasma protein purification and sterile production, supporting its vertically integrated business model. Its products are sold through partners, distributors, hospitals, pharmacies, and healthcare organizations across multiple countries, making the company a specialized supplier within the global plasma therapeutics market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$192M
▲ +12.1% YoY
Net Income (TTM)
$22M
▲ +39.7% YoY
Op. Margin
14.51%
▲ +2.1pp YoY
ROIC
8.19%
▲ +0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$26M
▼ -57.6% YoY
Op. Cash Flow (TTM)
$36M
▼ -43.0% YoY
Net Debt
-$64M
Net Cash Position
Cash & Equiv.
$75M
3Y CAGR: +11.7%
3Y CAGR: -14.2%
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with KMDA
Held by ETFs
KMDA is in 3 US ETFs. The largest of them, with KMDA's weight in each:
Kamada (KMDA) in four numbers
Questions about Kamada
Is Kamada (KMDA) overvalued?
At $7.74, Kamada's price is 23% below the $10.01 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 20.37 times earnings and 17.03 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Kamada's fair value?
Intrinsiqq's calculator puts Kamada's fair value at $10.01 a share. It grows earnings per share 11.6% a year for 5 years, applies an exit P/E of 21.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $7.50. Every input can be changed on the Intrinsic Value tab.
Is Kamada a high-quality business?
Kamada scores 66 out of 100 on Intrinsiqq's quality score, which makes it a solid business on these measures. The score blends 8 checks computed from company filings. Its best check is revenue growth at 10.4%, and its weakest is share count change at 24.7%. The Quality tab shows every check against its target.
Does Kamada (KMDA) pay a dividend, and how much?
Yes. Kamada (KMDA) pays a dividend: $0.25 per share over the last twelve months, a dividend yield of 3.29% at the latest close. It has raised its dividend per share for at least 1 year in a row (every year of the history we hold). The payout takes about 66.3% of earnings.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KMDA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.